[{"orgOrder":0,"company":"Azidus","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"BRAZIL","productType":"Antibiotic","year":"2010","type":"Inapplicable","leadProduct":"Tobramycin","moa":"70S ribosome","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Azidus","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Azidus \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Azidus \/ Undisclosed"},{"orgOrder":0,"company":"Unity Health Toronto","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"CANADA","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Tobramycin","moa":"70S ribosome","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Unity Health Toronto","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Unity Health Toronto \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Unity Health Toronto \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Antibiotic","year":"2014","type":"Inapplicable","leadProduct":"Tobramycin","moa":"70S ribosome","graph1":"Genetic Disease","graph2":"Phase IV","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Chiesi Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"ITALY","productType":"Antibiotic","year":"2010","type":"Inapplicable","leadProduct":"Tobramycin","moa":"70S ribosome","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Chiesi Group","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Chiesi Group \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Chiesi Group \/ Undisclosed"},{"orgOrder":0,"company":"Viatris","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibiotic","year":"2018","type":"Inapplicable","leadProduct":"Tobramycin","moa":"70S ribosome","graph1":"Genetic Disease","graph2":"Phase IV","graph3":"Viatris","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Viatris \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Viatris \/ Undisclosed"},{"orgOrder":0,"company":"Semler Research Center Pvt. Ltd.","sponsor":"Genzum Life Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"INDIA","productType":"Antibiotic","year":"2016","type":"Inapplicable","leadProduct":"Tobramycin","moa":"70S ribosome","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Semler Research Center Pvt. Ltd.","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Semler Research Center Pvt. Ltd. \/ Genzum Life Sciences","highestDevelopmentStatusID":"10","companyTruncated":"Semler Research Center Pvt. Ltd. \/ Genzum Life Sciences"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Antibiotic","year":"2013","type":"Inapplicable","leadProduct":"Tobramycin","moa":"70S ribosome","graph1":"Genetic Disease","graph2":"Phase IV","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Pari","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"GERMANY","productType":"Antibiotic","year":"2013","type":"Inapplicable","leadProduct":"Tobramycin","moa":"70S ribosome","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Pari","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Pari \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Pari \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Antibiotic","year":"2013","type":"Inapplicable","leadProduct":"Tobramycin","moa":"70S ribosome","graph1":"Genetic Disease","graph2":"Phase IV","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Antibiotic","year":"2014","type":"Inapplicable","leadProduct":"Tobramycin","moa":"70S ribosome","graph1":"Genetic Disease","graph2":"Phase IV","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Nebulizer","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Antibiotic","year":"2010","type":"Inapplicable","leadProduct":"Tobramycin","moa":"70S ribosome","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Powder for Inhalation","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Antibiotic","year":"2010","type":"Inapplicable","leadProduct":"Tobramycin","moa":"70S ribosome","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Solution","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Chiesi Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"ITALY","productType":"Antibiotic","year":"2010","type":"Inapplicable","leadProduct":"Tobramycin","moa":"70S ribosome","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Chiesi Group","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Solution","sponsorNew":"Chiesi Group \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Chiesi Group \/ Undisclosed"},{"orgOrder":0,"company":"University of Milan","sponsor":"Chiesi Group","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"ITALY","productType":"Antibiotic","year":"2012","type":"Inapplicable","leadProduct":"Tobramycin","moa":"70S ribosome","graph1":"Genetic Disease","graph2":"Phase IV","graph3":"University of Milan","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Milan \/ Chiesi Group","highestDevelopmentStatusID":"11","companyTruncated":"University of Milan \/ Chiesi Group"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Queen's University, Belfast | University Hospital Antwerp | University of Milan | Fundaci\u00f3 Cl\u00ednic per a la Recerca Biom\u00e8dica | Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation | Papworth Hospital NHS ","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"SWITZERLAND","productType":"Antibiotic","year":"2016","type":"Inapplicable","leadProduct":"Tobramycin","moa":"70S ribosome","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Queen's University, Belfast | University Hospital Antwerp | University of Milan | Fundaci\u00f3 Cl\u00ednic per a la Recerca Biom\u00e8dica | Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation | Papworth Hospital NHS ","highestDevelopmentStatusID":"8","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Queen's University, Belfast | University Hospital Antwerp | University of Milan | Fundaci\u00f3 Cl\u00ednic per a la Recerca Biom\u00e8dica | Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation | Papworth Hospital NHS "},{"orgOrder":0,"company":"Padagis","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Tobramycin","moa":"||70S ribosome","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Padagis","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Padagis \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Padagis \/ Undisclosed"},{"orgOrder":0,"company":"Padagis","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"ISRAEL","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Tobramycin","moa":"||70S ribosome","graph1":"Immunology","graph2":"Approved FDF","graph3":"Padagis","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Padagis \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Padagis \/ Undisclosed"},{"orgOrder":0,"company":"Eastern Virginia Medical School","sponsor":"Solsys Medical LLC | US Department of Defense","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2015","type":"Inapplicable","leadProduct":"Tobramycin","moa":"70S ribosome","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Eastern Virginia Medical School","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eastern Virginia Medical School \/ Solsys Medical LLC | US Department of Defense","highestDevelopmentStatusID":"7","companyTruncated":"Eastern Virginia Medical School \/ Solsys Medical LLC | US Department of Defense"},{"orgOrder":0,"company":"Mannkind","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Antibiotic","year":"2013","type":"Inapplicable","leadProduct":"Tobramycin","moa":"70S ribosome","graph1":"Undisclosed","graph2":"Phase I","graph3":"Mannkind","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Mannkind \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Mannkind \/ Undisclosed"},{"orgOrder":0,"company":"Sutphin Drugs","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Antibiotic","year":"2019","type":"Inapplicable","leadProduct":"Tobramycin","moa":"70S ribosome","graph1":"Ophthalmology","graph2":"Phase I","graph3":"Sutphin Drugs","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Sutphin Drugs \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Sutphin Drugs \/ Undisclosed"},{"orgOrder":0,"company":"Alcon Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Antibiotic","year":"2010","type":"Inapplicable","leadProduct":"Tobramycin","moa":"70S ribosome","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Alcon Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Alcon Inc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Alcon Inc \/ Undisclosed"},{"orgOrder":0,"company":"Sonoran Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Tobramycin","moa":"||70S ribosome","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Sonoran Biosciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sonoran Biosciences \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Sonoran Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation","sponsor":"Chiesi Group","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Antibiotic","year":"2015","type":"Inapplicable","leadProduct":"Tobramycin","moa":"70S ribosome","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation \/ Chiesi Group","highestDevelopmentStatusID":"11","companyTruncated":"Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation \/ Chiesi Group"},{"orgOrder":0,"company":"Erempharma","sponsor":"University of Lyon | Epidemiologie Pharmacologie Investigation Clinique Information medicale Mere Enfant | Clininfo | Hospices Civils de Lyon","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Antibiotic","year":"2011","type":"Inapplicable","leadProduct":"Tobramycin","moa":"70S ribosome","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Erempharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Erempharma \/ University of Lyon | Epidemiologie Pharmacologie Investigation Clinique Information medicale Mere Enfant | Clininfo | Hospices Civils de Lyon","highestDevelopmentStatusID":"7","companyTruncated":"Erempharma \/ University of Lyon | Epidemiologie Pharmacologie Investigation Clinique Information medicale Mere Enfant | Clininfo | Hospices Civils de Lyon"},{"orgOrder":0,"company":"Pharmaero","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"","productType":"Antibiotic","year":"2014","type":"Inapplicable","leadProduct":"Tobramycin","moa":"70S ribosome","graph1":"Undisclosed","graph2":"Phase I","graph3":"Pharmaero","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pharmaero \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Pharmaero \/ Undisclosed"},{"orgOrder":0,"company":"Amneal Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Steroid","year":"2021","type":"Inapplicable","leadProduct":"Dexamethasone","moa":"||Glucocorticoid receptor","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Amneal Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Amneal Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Amneal Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Osteal Therapeutics","sponsor":"Hm Capital","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2022","type":"Series B Financing","leadProduct":"Tobramycin","moa":"||Peptidoglycan","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Osteal Therapeutics","amount2":0.029999999999999999,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.029999999999999999,"dosageForm":"Undisclosed","sponsorNew":"Osteal Therapeutics \/ Hm Capital","highestDevelopmentStatusID":"8","companyTruncated":"Osteal Therapeutics \/ Hm Capital"},{"orgOrder":0,"company":"Osteal Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Tobramycin","moa":"||Peptidoglycan","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Osteal Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Osteal Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Osteal Therapeutics \/ Undisclosed"}]

Find Clinical Drug Pipeline Developments & Deals for Tobramycin

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          OTS 2025
                          Not Confirmed
                          OTS 2025
                          Not Confirmed

                          Details : VT-X7, (Vancomycin Hydrochloride), a drug/device combination product that locally delivers, via irrigation, highly targeted antibiotic therapy to the hip or knee during an accelerated seven-day interstage period of a two-stage exchange arthroplasty.

                          Product Name : Undisclosed

                          Product Type : Antibiotic

                          Upfront Cash : Inapplicable

                          November 04, 2022

                          Lead Product(s) : Vancomycin HCl,Tobramycin

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase II

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          OTS 2025
                          Not Confirmed
                          OTS 2025
                          Not Confirmed

                          Details : Tobramycin (generic to Tobradex) Ophthalmic Suspension is indicated for steroid-responsive inflammatory ocular conditions for which a corticosteroid is indicated and where superficial bacterial ocular infection or a risk of bacterial ocular infection exi...

                          Product Name : Tobramycin / Dexamethasone-Generic

                          Product Type : Antibiotic

                          Upfront Cash : Inapplicable

                          March 21, 2022

                          Lead Product(s) : Tobramycin,Dexamethasone

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Approved FDF

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          OTS 2025
                          Not Confirmed
                          OTS 2025
                          Not Confirmed

                          Details : Tobradex® Ophthalmic Suspension is indicated for steroid-responsive inflammatory ocular conditions for which a corticosteroid is indicated and where superficial bacterial ocular infection or a risk of bacterial ocular infection exists.

                          Product Name : Tobramycin / Dexamethasone-Generic

                          Product Type : Antibiotic

                          Upfront Cash : Inapplicable

                          March 21, 2022

                          Lead Product(s) : Tobramycin,Dexamethasone

                          Therapeutic Area : Immunology

                          Highest Development Status : Approved FDF

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          OTS 2025
                          Not Confirmed
                          OTS 2025
                          Not Confirmed

                          Details : The proceeds will enable Osteal to continue development of its integrated technologies, advance the clinical development of its lead candidate, VT-X7 for treatment of periprosthetic joint infection and fund new research programs.

                          Product Name : Undisclosed

                          Product Type : Antibiotic

                          Upfront Cash : Undisclosed

                          March 08, 2022

                          Lead Product(s) : Vancomycin HCl,Tobramycin

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase II

                          Sponsor : Hm Capital

                          Deal Size : $30.0 million

                          Deal Type : Series B Financing

                          blank

                          05

                          OTS 2025
                          Not Confirmed
                          OTS 2025
                          Not Confirmed

                          Details : Dexamethasone & Tobramycin Ophthalmic Suspension 0.3%/0.1% is generic version of TobraDex, which is indicated for steroid-responsive inflammatory ocular conditions for which a corticosteroid is indicated and where superficial bacterial ocular infection o...

                          Product Name : Undisclosed

                          Product Type : Steroid

                          Upfront Cash : Inapplicable

                          July 19, 2021

                          Lead Product(s) : Dexamethasone,Tobramycin

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Approved FDF

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          06

                          OTS 2025
                          Not Confirmed
                          OTS 2025
                          Not Confirmed

                          Details : Sonoran's lead product SBG003 (tobramycin and vancomycin hydrogel) has been granted Qualified Infectious Disease Product (QIDP) designation by the U.S. Food & Drug Administration (FDA) for prevention of post-abdominal surgical site infection.

                          Product Name : Undisclosed

                          Product Type : Antibiotic

                          Upfront Cash : Inapplicable

                          August 03, 2020

                          Lead Product(s) : Tobramycin,Vancomycin HCl

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Preclinical

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          07

                          OTS 2025
                          Not Confirmed
                          OTS 2025
                          Not Confirmed

                          Details : Tobramycin is a Antibiotic drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Blepharo Conjunctivitis.

                          Product Name : Undisclosed

                          Product Type : Antibiotic

                          Upfront Cash : Inapplicable

                          June 05, 2019

                          Lead Product(s) : Tobramycin

                          Therapeutic Area : Ophthalmology

                          Highest Development Status : Phase I

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          08

                          OTS 2025
                          Not Confirmed
                          OTS 2025
                          Not Confirmed

                          Details : Tobi Podhaler is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Cystic Fibrosis.

                          Product Name : Undisclosed

                          Product Type : Antibiotic

                          Upfront Cash : Inapplicable

                          April 18, 2018

                          Lead Product(s) : Tobramycin

                          Therapeutic Area : Genetic Disease

                          Highest Development Status : Phase IV

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          09

                          Semler Research Center Pvt. Ltd.

                          Country arrow
                          OTS 2025
                          Not Confirmed

                          Semler Research Center Pvt. Ltd.

                          Country arrow
                          OTS 2025
                          Not Confirmed

                          Details : Tobramycin is a Antibiotic drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Cataract.

                          Product Name : Undisclosed

                          Product Type : Antibiotic

                          Upfront Cash : Inapplicable

                          April 12, 2016

                          Lead Product(s) : Tobramycin

                          Therapeutic Area : Ophthalmology

                          Highest Development Status : Phase III

                          Sponsor : Genzum Life Sciences

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          10

                          OTS 2025
                          Not Confirmed
                          OTS 2025
                          Not Confirmed

                          Lead Product(s) : Tobramycin

                          Therapeutic Area : Pulmonary/Respiratory Diseases

                          Study Phase : Phase II

                          Sponsor : Queen's University, Belfast | University Hospital Antwerp | University of Milan | Fundació Clínic per a la Recerca Biomèdica | Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation | Papworth Hospital NHS

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Details : Tobramycin is a Antibiotic drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Bronchiectasis.

                          Product Name : Undisclosed

                          Product Type : Antibiotic

                          Upfront Cash : Inapplicable

                          March 18, 2016

                          Lead Product(s) : Tobramycin

                          Therapeutic Area : Pulmonary/Respiratory Diseases

                          Highest Development Status : Phase II

                          Sponsor : Queen's University, Belfast | University Hospital Antwerp | University of Milan | Fundació Clínic per a la Recerca Biomèdica | Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation | Papworth Hospital NHS

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank